Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 75% Improvement Relative Risk c19ivm.org Hill et al. Ivermectin for COVID-19 META ANALYSIS Favors ivermectin Favors control
Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
Hill et al., Research Square, doi:10.21203/rs.3.rs-148845/v1 (Preprint) (meta analysis)
Hill et al., Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection, Research Square, doi:10.21203/rs.3.rs-148845/v1 (Preprint) (meta analysis)
Jan 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Meta analysis of 18 ivermectin RCTs with 2,282 patients showing faster viral clearance (dose and duration dependent), improved clinical recovery, and lower hospitalization and mortality. In six RCTs of moderate or severe infection, there was a 75% reduction in mortality, RR 0.25 [0.12-0.52], p = 0.0002.
A documentary about the external influences changing the conclusions of this study, and the resulting negative impacts, can be found at [drtesslawrie.substack.com].
A sponsor reportedly required the conclusion of this paper to be changed against the wishes of the authors (to suggest that more trials should be done as opposed to the existing evidence being sufficient) [francesoir.fr, reddit.com, youtube.com]. Reportedly, Unitaid had influence over the conclusions [trialsitenews.com, worldcouncilforhealth.org]. See also [roundingtheearth.substack.com].
Note that one of the 18 studies in this analysis has since been withdrawn (Elgazzar).
Currently there are 95 ivermectin studies and meta analysis shows:
OutcomeImprovement
Mortality51% lower [37‑62%]
Ventilation29% lower [13‑42%]
ICU admission41% lower [16‑58%]
Hospitalization34% lower [20‑45%]
Cases78% fewer [67‑85%]
risk of death, 75.0% lower, RR 0.25, p < 0.001.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hill et al., 19 Jan 2021, preprint, 40 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection Andrew Hill (  andrewhillmv@gmail.com ) University of Liverpool Ahmed Abdulamir College of Medicine, Alnahrain University, Baghdad, Iraq Sabeena Ahmed International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh, Asma Asghar Department of Medicine, Combined Military Hospital, Lahore, Pakistan Olufemi Emmanuel Babalola Bingham University / Lagos University, Nigeria Rabia Basri Fatima Memorial Hospital, Lahore, Pakistan Carlos Chaccour Barcelona Institute for Global Health, Clinica Universidad de Navarra, Spain Aijaz Zeeshan Khan Chachar Fatima Memorial Hospital, Lahore, Pakistan Abu Tauib Mohammed Chowdhury Xi'an Jiaotong University Medical College First A liated Hospital, Shaannxi, China Ahmed Elgazzar Faculty of Medicine, Benha University, Benha, Egypt Leah Ellis Faculty of Medicine, Imperial College, London, UK Jonathan Falconer Department of Infectious Diseases, Chelsea and Westminster Hospital, London, UK Anna Garratt Department of Infectious Diseases, University Hospital of Wales, Cardiff and Vale University Health Board, UK Basma Hany Faculty of Medicine, Benha University, Benha, Egypt Hashim A Hashim Alkarkh Hospital, Alate ya, Baghdad, Iraq Wasim Ul Haque Department of Nephrology, BIRDEM General Hospital, Dhaka, Bangladesh Arshad Hayat Department of Medicine, Combined Military Hospital, Lahore, Pakistan Shuixiang He Xi'an Jiaotong University Medical College First A liated Hospital, Shaanxi, China Ramin Jamshidian Jundishapur University School of Medical Sciences, Ahvaz, Iran Wasif Ali Khan International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh Ravi Kirti Department of General Medicine, All India Institute of Medical Sciences, Patna, India Alejandro Krolewiecki Instituto de Investigatiaciones de Enferedades Tropicales, Sede Regional Oran, Universidad National de Salta, Argentina Carlos Lanusse Laboratorio de Farmacologia, Universidad de Buenos Aires, Argentina Jacob Levi Department of Intensive Care, University College London, UK Reaz Mahmud Department of Neurology, Dhaka Medical College, Dhaka, Bangladesh Sermand Ahmed Mangat Department of Medicine, Combined Military Hospital, Lahore, Pakistan Kaitlyn McCann Faculty of Medicine, Imperial College, London, UK Anant Mohan Department of Pulmonary Critical Care and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India Mortezza Shakshi Niaee Qazvin Science and Technology Park, Qazvin, Iran Nurullah Okumus Department of Neonatology, Afyonkarahisar Health Sciences University, Afkonkarahisar, Turkey Victoria Pilkington Oxford University, Clinical Academic Graduate School, University of Oxford, UK Chinmay Saha Podder Debidwar Upazila Health Complex, Debidwar, Comilla, Bangladesh Ambar Qavi Faculty of Medicine, Imperial College, London, UK Houssam Raad Biotherapies e Maladies Genetiques et Cancer, Universite Bordeaux, Segalen, France Mohammaed Sadegh Rezai Pediatric Infectious Diseases Research Centre, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, India Surapaneni Sasank Gandhi University, Andhra Pradesh, India Veerapaneni Spoorthi Apollo Medical College, Hyderabad, India Tejas Suri Qazvin Science and Technology Park, Qazvin, Iran Junzheng Wang Faculty of Medicine, Imperial College, London, UK Hannah Wentzel Faculty of Medicine, Imperial College, London Systematic Review Keywords: ivermectin, COVID-19, SARS-CoV-2 Posted Date:..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit